Ildong enters imaging market with Meditec purchase
This article was originally published in Clinica
South Korean pharmaceutical company Ildong Pharm plans to enter the diagnostic equipment business with the purchase of a 51% stake in Meditec. Ildong aims to boost the diagnostic imaging company into the top five in South Korea by acquiring advanced technology from Japan and other countries, reports Pharma Koreana. It also intends to construct and operate a high-tech hospital.
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.